secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001193125-24-156202
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics shareholders approve reverse stock split and elect three directors
--------------------------------------------------------------------------------

- Approved 1-for-10 reverse stock split with 31,461,878 votes for, 1,019,669 against, 78,724 abstentions.
- Elected Class II directors Dirk Thye, David Lamond, and Luca Benatti to serve until 2027 annual meeting.
- Ratified BDO USA as independent registered accounting firm for fiscal year ending Dec 31, 2024.
- Advisory say-on-pay approved: 17,945,554 for, 429,833 against, 94,767 abstentions (14,090,117 broker non-votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524156202/0001193125-24-156202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524156202/d844037d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-156202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer